Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions - Top-Institutions - MDSpire

Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions

  • By

  • Kadiatou Traore

  • Francesca Castro

  • Andriy Derkach

  • Elan Gorshein

  • Edith Serrano

  • Alankrita Taneja

  • Jorge Arturo Hurtado Martínez

  • Alexander M. Lesokhin

  • Ana M. Sahagun Sanchez Aldana

  • Patricia Alejandra Flores Pérez

  • Saad Z. Usmani

  • Jenifer M. Ahlstrom

  • Torin Block

  • Jay R. Hydren

  • Cynthia A. Thomson

  • Urvi A. Shah

  • March 27, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Nutritional Epidemiology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Cancer Nutrition

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Clinical Nutrition

  • #4

    University of California San Francisco (UCSF) Medical Center
    University of California San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Nutritional Science

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Nutritional Epidemiology

Original Source(s)

Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions

  • by Kadiatou Traore, Francesca Castro, Andriy Derkach, Elan Gorshein, Edith Serrano, Alankrita Taneja, Jorge Arturo Hurtado Martínez, Alexander M. Lesokhin, Ana M. Sahagun Sanchez Aldana, Patricia Alejandra Flores Pérez, Saad Z. Usmani, Jenifer M. Ahlstrom, Torin Block, Jay R. Hydren, Cynthia A. Thomson, Urvi A. Shah

  • March 27, 2026

Related Content

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database